Biocure Technology Management

Management criteria checks 3/4

Biocure Technology's CEO is Simon Cheng, appointed in Sep 2023, has a tenure of 1.83 years. total yearly compensation is CA$15.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.038% of the company’s shares, worth CA$291.67. The average tenure of the management team and the board of directors is 6.8 years and 7.4 years respectively.

Key information

Simon Cheng

Chief executive officer

CA$15.0k

Total compensation

CEO salary percentage100.00%
CEO tenure1.8yrs
CEO ownership0.04%
Management average tenure6.8yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Simon Cheng's remuneration changed compared to Biocure Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-CA$245k

Dec 31 2024CA$15kCA$15k

-CA$262k

Sep 30 2024n/an/a

-CA$4m

Jun 30 2024n/an/a

-CA$4m

Mar 31 2024n/an/a

-CA$1m

Dec 31 2023CA$10kCA$10k

-CA$1m

Compensation vs Market: Simon's total compensation ($USD11.02K) is below average for companies of similar size in the Canadian market ($USD171.07K).

Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.


CEO

Simon Cheng (44 yo)

1.8yrs
Tenure
CA$15,000
Compensation

Mr. Yee Sing Cheng, also known as Simon, is Independent Director of Rush Gold Corp. from February 3, 2025. He serves as CEO & Director at Biocure Technology Inc. since September 8, 2023. He is Director of...


Leadership Team

NamePositionTenureCompensationOwnership
Yee Cheng
CEO & Director1.8yrsCA$15.00k0.038%
CA$ 291.7
Konstantin Lichtenwald
CFO, Corporate Secretary & Director7.3yrsCA$110.00k1.92%
CA$ 14.9k
Marco Nonni
Consultant6.8yrsCA$16.50kno data
6.8yrs
Average Tenure

Experienced Management: CURE.X's management team is seasoned and experienced (6.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yee Cheng
CEO & Director1.8yrsCA$15.00k0.038%
CA$ 291.7
Konstantin Lichtenwald
CFO, Corporate Secretary & Director7.3yrsCA$110.00k1.92%
CA$ 14.9k
Sang Kim
Independent Director9.9yrsCA$90.00k2.54%
CA$ 19.6k
Jae Shin
Member of Advisory Board7.4yrsno datano data
Hyun Lee
Member of Advisory Board7.4yrsno datano data
Heon Lee
Member of Advisory Board7.4yrsno datano data
7.4yrs
Average Tenure
44yo
Average Age

Experienced Board: CURE.X's board of directors are considered experienced (7.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/06 20:37
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biocure Technology Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.